Vintafolide
{{Drugbox | IUPAC_name =N-(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-γ-glutamyl-L-α-aspartyl-L-arginyl-L-α-aspartyl-L-α-aspartyl-L-cysteine disulfide with methyl (5S,7R,9S)-5-ethyl-9-[(3aR,4R,5S,5aR,10bR,13aR)-3a-ethyl-4,5-dihydroxy-8-methoxy-6-methyl-5-({2-[(2-sulfanylethoxy)carbonyl]hydrazinyl}carbonyl)-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazol-9-yl]-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indol-9-carboxylate | synonyms = EC-145 | image = Vintafolide.png | width = 250px | alt = Vintafolide structure | image2 = | width2 =
| Drugs.com = | MedlinePlus = | pregnancy_category = | legal_status = IND | routes_of_administration =
| bioavailability = | metabolism = | elimination_half-life = | excretion =
| CAS_number_Ref = 
| CAS_number = 742092-03-1
| ATC_prefix = L01
| ATC_suffix = CA06
| PubChem =
| IUPHAR_ligand =
| DrugBank_Ref =
| DrugBank =
| ChemSpiderID_Ref =
| ChemSpiderID = 27444385
| UNII_Ref =
| UNII =
| KEGG_Ref =
| KEGG =
| ChEBI_Ref =
| ChEBI =
| ChEMBL_Ref =
| ChEMBL =
| C=86 | H=109 | N=21 | O=26 | S=2 |
| molecular_weight = 1917 g/mol
| smiles = [H]/N=C(\N)/NCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CSSCCOC(=O)NNC(=O)[C@@]1([C@H]2[C@]3(CCN4[C@H]3[C@]([C@H]1O)(C=CC4)CC)c5cc(c(cc5N2C)OC)[C@]6(C[C@@H]7C[C@](CN(C7)CCc8c6[nH]c9c8cccc9)(CC)O)C(=O)OC)O)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CC[C@@H](C(=O)O)NC(=O)c1ccc(cc1)NCc1cnc2c(n1)c(=O)[nH]c(n2)N
| StdInChI = 1S/C86H109N21O26S2/c1-6-82(129)35-42-36-85(78(127)132-5,64-47(21-26-106(39-42)41-82)46-12-8-9-13-50(46)95-64)49-30-48-57(34-58(49)131-4)105(3)75-84(48)23-27-107-25-11-22-83(7-2,74(84)107)76(125)86(75,130)77(126)103-104-81(128)133-28-29-134-135-40-56(73(123)124)100-70(119)55(33-62(113)114)99-69(118)54(32-61(111)112)98-67(116)51(14-10-24-90-79(87)88)96-68(117)53(31-60(109)110)94-59(108)20-19-52(72(121)122)97-66(115)43-15-17-44(18-16-43)91-37-45-38-92-65-63(93-45)71(120)102-80(89)101-65/h8-9,11-13,15-18,22,30,34,38,42,51-56,74-76,91,95,125,129-130H,6-7,10,14,19-21,23-29,31-33,35-37,39-41H2,1-5H3,(H,94,108)(H,96,117)(H,97,115)(H,98,116)(H,99,118)(H,100,119)(H,103,126)(H,104,128)(H,109,110)(H,111,112)(H,113,114)(H,121,122)(H,123,124)(H4,87,88,90)(H3,89,92,101,102,120)/t42-,51-,52-,53-,54-,55-,56-,74-,75+,76+,82-,83+,84+,85-,86-/m0/s1
| StdInChI_Ref =
| StdInChIKey_Ref =
| StdInChIKey = KUZYSQSABONDME-QRLOMCMNSA-N
}}
|
WikiDoc Resources for Vintafolide |
|
Articles |
|---|
|
Most recent articles on Vintafolide Most cited articles on Vintafolide |
|
Media |
|
Powerpoint slides on Vintafolide |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Vintafolide at Clinical Trials.gov Clinical Trials on Vintafolide at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Vintafolide
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Vintafolide Discussion groups on Vintafolide Patient Handouts on Vintafolide Directions to Hospitals Treating Vintafolide Risk calculators and risk factors for Vintafolide
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Vintafolide |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]
Overview
Vintafolide is an investigational targeted cancer therapeutic currently under development by Endocyte and Merck & Co.[1] It is a small molecule drug conjugate consisting of a small molecule targeting the folate receptor, which is overexpressed on certain cancers, such as ovarian cancer, and a potent chemotherapy drug, vinblastine.[2] It is being developed with a companion imaging agent, etarfolatide, that identifies patients that express the folate receptor and thus would likely respond to the treatment with vintafolide.[3] A Phase 3 study evaluating vintafolide for the treatment of platinum-resistant ovarian cancer (PROCEED trial) and a Phase 2b study(TARGET trial) in non-small-cell lung carcinoma (NSCLC) are ongoing.[4] Vintafolide is designed to deliver the toxic vinblastine drug selectively to cells expressing the folate receptor using folate targeting.[5]
A Marketing Authorization Application (MAA) filing for vintafolide and etarfolatide for the treatment of patients with folate receptor-positive platinum-resistant ovarian cancer in combination with doxorubicin, pegylated liposomal doxorubicin (PLD), has been accepted by the European Medicines Agency.[6] The drug received an orphan drug status in Europe in March 2012.[7] Merck & Co. acquired the development and marketing rights to this experimental cancer drug from Endocyte in April 2012.[8] The drug received orphan drug status in Europe in March 2012.[3] Endocyte remains responsible for the development and commercialization of etarfolatide, a non-invasive companion imaging agent used to identify patients expressing the folate receptor that will likely respond to treatment with vintafolide.[9] Vintafolide is designed to deliver the toxic vinblastine drug selectively to cells expressing the folate receptor using folate targeting.[10]
Merck ($MRK) and partner Endocyte ($ECYT) have stopped a late-stage study of the ovarian cancer-treating vintafolide on the advice of a data safety monitoring board, saying the much-hyped drug failed to move the needle on progression-free survival.[11]
Mechanism of action
Folate is required for cell division, and rapidly dividing cancer cells often express folate receptors in order to capture enough folate to support rapid cell growth. Elevated expression of the folate receptor occurs in many diseases, including other aggressively growing cancers and inflammatory disorders.[12] Vintafolide binds to the folate receptor and is subsequently taken up by the cell through a natural internalization process called endocytosis. Once inside the cell, vintafolide’s linker releases the chemotherapy drug which kills the cell.[13]
References
- ↑ http://www.reuters.com/article/2012/04/16/us-merck-idUSBRE83F0W120120416%7D%7D. Missing or empty
|title=(help)[dead link] - ↑ Statement on a nonproprietary name adopted by the USAN Council, United States Adopted Names (USAN) Council, 6 April 2012
- ↑ [1]
- ↑ http://www.dddmag.com/news/2012/04/merck-endocyte-development-deal
- ↑ PMID 21154124 (PMID 21154124)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ http://www.rttnews.com/2012700/ema-accepts-for-review-maa-filings-for-vintafolide-and-etarfolatide.aspx
- ↑ Sridharan, Balaji (Apr 16, 2012). "Endocyte soars on cancer drug deal with Merck". Reuters, US Edition.
- ↑ Sridharan, Balaji (16 April 2012). "Endocyte soars on cancer drug deal with Merck". Reuters.
- ↑ http://www.dddmag.com/news/2012/04/merck-endocyte-development-deal
- ↑ PMID 21154124 (PMID 21154124)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ http://www.fiercebiotech.com/story/merck-halts-study-billion-dollar-cancer-drug-vintafolide/2014-05-02
- ↑ "Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay". 338 (2). March 2005: 284–93. doi:10.1016/j.ab.2004.12.026. PMID 15745749.
- ↑ http://www.radiologytoday.net/archive/rt0213p12.shtml